Table 1.

Incidence of OFT malformations after ablation of Fgfr1/2 with Mesp1Cre or Isl1Cre, or activation of Spry2-GOFwith Mesp1Cre

Fgfr1/2 ablation with Mesp1Cre
 
          
 No Cre
 
    Mesp1Cre
 
    
Fgfr1;Fgfr2
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
Normal 14 31 14 12 19  
Alignment      2   7 DORV  
PTA type 1           
PTA type III          4†† 
VSD        1§ 8 
BAV      ND   4** 
ASD        
n 14 31 14 14 18 10 18 
Expected n
 
14
 
5
 
20
 
5
 
20
 
14
 
18
 
7
 
18
 
7
 
Fgfr1/2 ablation with Isl1Cre
 
          
 No Cre
 
    Isl1Cre
 
    
Fgfr1;Fgfr2
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
Normal 20 13 11 11 15   
Alignment      2‡‡  4§§   
PTA type I         
PTA type III         
VSD      6¶¶   
BAV        3***  
ASD        
n 20 13 11 11 14 15 13 
Expected n
 
18
 
11
 
11
 
11
 
11
 
18
 
11
 
11
 
11
 
11
 
Activation of Spry2-GOF with Mesp1Cre
 
          
 Spry2-GOF;Mesp1Cre
 
         

 
Control
 
Mutant
 

 

 

 

 

 

 

 

 
Normal 19         
Alignment          
PTA type I          
PTA type III          
VSD          
BAV          
AVCD          
n 19 13         
Fgfr1/2 ablation with Mesp1Cre
 
          
 No Cre
 
    Mesp1Cre
 
    
Fgfr1;Fgfr2
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
Normal 14 31 14 12 19  
Alignment      2   7 DORV  
PTA type 1           
PTA type III          4†† 
VSD        1§ 8 
BAV      ND   4** 
ASD        
n 14 31 14 14 18 10 18 
Expected n
 
14
 
5
 
20
 
5
 
20
 
14
 
18
 
7
 
18
 
7
 
Fgfr1/2 ablation with Isl1Cre
 
          
 No Cre
 
    Isl1Cre
 
    
Fgfr1;Fgfr2
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
c/c;+/+*
 
c/+;c/+
 
c/+;c/c
 
c/c;c/+
 
c/c;c/c
 
Normal 20 13 11 11 15   
Alignment      2‡‡  4§§   
PTA type I         
PTA type III         
VSD      6¶¶   
BAV        3***  
ASD        
n 20 13 11 11 14 15 13 
Expected n
 
18
 
11
 
11
 
11
 
11
 
18
 
11
 
11
 
11
 
11
 
Activation of Spry2-GOF with Mesp1Cre
 
          
 Spry2-GOF;Mesp1Cre
 
         

 
Control
 
Mutant
 

 

 

 

 

 

 

 

 
Normal 19         
Alignment          
PTA type I          
PTA type III          
VSD          
BAV          
AVCD          
n 19 13         

Note that the total number of defects exceeds n because specimens have more than one defect.

+, wild-type allele; c, conditional allele.

ND, not determined.

*

Fgfr1 single-mutant analyses obtained from separate breedings.

iViesp1 and Fgfr2 linkage results in non-Mendelian distribution.

One TGA, one DORV.

§

Inlet VSD (ventricular septal defect).

Seven with DORV, one with BAV (bicuspid aortic valve).

**

Two isolated, one with VSD, one with DORV.

††

One with atrioventricular canal defect (AVCD).

‡‡

One TGA, one DORV.

§§

Two DORV, two posteriorly rotated aorta.

¶¶

Three associated with OFT defects, three with BAV.

***

All associated with VSD.

Close Modal

or Create an Account

Close Modal
Close Modal